JSC "Pharmstandard" is the leading pharmaceutical company in Russia, engaged in the development and production of modern, high-quality, affordable medicines that meet the requirements of healthcare and the expectations of patients.

The Company's best-known drugs today are Arbidol®, Complivit®, Pentalgin®, Flucostat®, Phosphogliv®, Amiksin®, Afobazol®, Rastan® and Biosulin®. Pharmstandard group of companies produces more than 250 items medicines, including drugs for the treatment of cardiovascular diseases, diabetes mellitus, growth hormone deficiency, gastroenterological, neurological, infectious diseases, metabolic disorders, oncological and other diseases. More than 120 drugs (taking into account all forms and dosages) are included in the "List of vital and essential drugs."

Since 2004, more than 60 new drugs have been developed and introduced in cooperation with leading research centers in Russia.

JSC "Pharmstandard" is a member of the joint biotechnological project "Generium" for the development and production of socially significant drugs within the framework of state program import substitution.

Cumulative production capacity allow the company to produce more than 1.7 billion packages per year. The Pharmstandard group of companies' production facilities are provided by 8 modern factories for the production of medicines: Pharmstandard-Leksredstva OJSC (Kursk), Pharmstandard-UfaVITA OJSC (Ufa), Pharmstandard-Tomskhimfarm OJSC (Tomsk) , PJSC "Pharmstandard-Biolek" (Kharkov, Ukraine), OJSC "Biomed" named after. I. I. Mechnikov (Moscow, Moscow region), LLC "PHARMAPARK" (Moscow), CJSC "Lekko" (Vladimir region, settlement Volginsky) and the plant of medical equipment JSC "TZMOI", Tyumen. Pharmstandard LLC (Moscow), which purchases and supplies raw materials for the further production of pharmaceutical products at the production sites of factories that are part of the Pharmstandard group of companies.

All production facilities of the Company fully meet the requirements Russian standards. 6 production lines of JSC "Pharmstandard-Leksredstva" received certificates of compliance with European standards European Union Good Manufacturing Practice (European standards of good industrial practice). The Company's management has approved a program for the transition of plants to European GMP standards by 2014.

On May 4, 2007, Pharmstandard OJSC held a public offering of shares (Initial Public Offering, IPO). Shares and GDRs of Pharmstandard OJSC are traded on the MICEX-RTS and LSE (London Stock Exchange), respectively.

(ISIC : 21)

Production capacity

The total production capacity allows the company to produce more than 1.7 billion packages per year. The production facilities of the Pharmstandard group of companies are provided by 9 factories for the production of medicines:

• Russia Russia: Kursk, Pharmstandard-Leksredstva JSC
• Russia Russia: Ufa , JSC Pharmstandard-UfaVITA
• Russia Russia: Tomsk , JSC "Pharmstandard-Tomskhimfarm"
• Russia Russia: Moscow region, JSC "Biomed" them. I. I. Mechnikova
• Russia Russia Location: Moscow, PHARMAPARK LLC
• Russia Russia: Vladimir region, CJSC "Lekko"
• Russia Russia: Tyumen , JSC "TZMOI"
• Ukraine Ukraine: Kharkiv , Pharmstandard-Biolek PJSC
• Singapore Singapore: Bever Pharmaceutical PTE Ltd

Story

Pharmstandard was founded in 2003 by Profit House (a Millhouse Capital structure that managed Roman Abramovich's assets). By that time, the company owned only two Russian pharmaceutical plants: Fitopharm-NN in Nizhny Novgorod and Ufavita in Ufa. Five more were purchased from the American pharmaceutical giant ICN Pharmaceuticals: October in St. Petersburg, Marbiopharm in Yoshkar-Ola, Leksredstva in Kursk, Polifarm in Chelyabinsk and Tomskhimfarm in Tomsk.

Subsequently, three factories were sold or closed for various reasons: Oktyabr (inconveniently located in the very center of the city), Marbiopharm (focused on the production of substances secondary to the Pharmstandard strategy), Polipharm (required too much investment).

In 2005, Pharmstandard bought the Tyumen Plant of Medical Equipment and Instruments.

By 2006, the company spent more than $70 million to bring production in line with international GMP quality standards.

In 2006, Pharmstandard bought Masterlek, which had 15 famous brands. In particular, the rights to Arbidol, Amiksin and Flukostat were obtained. By that time, the holding's production capacity exceeded 1 billion packs per year; all forms of medicines (tablets, suspensions, capsules, sprays) were produced at the Pharmstandard factories. By the end of the year, Arbidol came out on top in sales in Russia, pushing hawthorn tincture aside.

In 2006, the company launched several more high-tech drugs into production: the first growth hormone in Russia, Rastan, developed at the Institute of Bioorganic Chemistry, and genetically engineered human insulin Biosulin. At the moment Pharmstandard is the largest Russian manufacturer of insulin. The company's capacity would be enough to meet 100% of the needs of Russians in this drug, but so far Russia imports most of the insulin from abroad.

Since 2007, Pharmstandard has been actively working with foreign partners: for example, at Tomskhimfarm, together with Solvay Pharma (France), the production of drugs IRS19 and Imudon has begun.

In 2008, Pharmstandard entered into an agreement with the Latvian enterprise "Grindeks" (Latvia) for the exclusive distribution and promotion of the drug Mildronate, mastering the production of Afobazol, introducing the genetically engineered drug Neipomax into production.

In 2009, Pharmstandard became the first and currently the only Russian member of the International Council of Producers, Distributors and Consumers of Active Pharmaceutical Ingredients (Excipients) in Europe (IPEC Europe). In the same year, the company implemented an operation to introduce a specialized IP solution for the central office and factories.

In 2009, Pharmstandard became the first Russian full member of the International Pharmaceutical Excipients Council Europe (IPEC Europe) International Council of Manufacturers, Distributors and Consumers of Active Pharmaceutical Ingredients (Excipients) in Europe.

In 2010, the Rostec State Corporation and Pharmstandard OJSC signed a cooperation agreement.

In 2010, Pharmstandard announces the acquisition of 100% of the shares of CJSC Vindexpharm.

In 2011, Pharmstandard announces the acquisition of a 55% stake in Biolek PJSC (Ukraine).

In 2011, Pharmstandard was recognized as the most influential Russian pharmaceutical manufacturer.

In 2012, Pharmstandard OJSC announces that Pharmstandard-UfaVITA OJSC and Pharmstandard-Leksredstva OJSC have joined the Association of Pharmaceutical Manufacturers of the Eurasian Economic Community.

In 2012, Pharmstandard OJSC acquired 50.1% of Bigpearl Trading Ltd. and 100% ZAO LEKKO. The amount of investments did not exceed $80 million.

In 2013, Pharmstandard OJSC bought 100% of Singapore's Bever pharmaceutical PTE Ltd for $590 million.

In 2018, Pharmstandard OJSC becomes the 100% owner of the PET-technology network of nuclear medicine centers, having bought the remaining 49.9% from Rosnano. The deal amounted to 2.9 billion rubles.

In August 2018, Pharmstandard entered into an agreement with the American biopharmaceutical company Gilead (Gilead Sciences) on the production of Sovaldi (Sofosbuvir) for the treatment of chronic hepatitis C and Truvada (Tenofovir/emtricitabine) for the treatment of HIV at Pharmstandard's facilities.

Owners and management

CEO- Grigory Potapov. Chairman of the Board of Directors - Viktor Kharitonin.

The main owner of the company is Augment Investments Ltd (54.32%, owned by Viktor Kharitonin and Yegor Kulkov), 9.68% of the shares are traded on the MICEX and RTS, 27.56% in the form of GDRs - on the London Stock Exchange. In March 2008, Roman Abramovich, Evgeny Shvidler and Millhouse Capital Management, who previously owned large stakes in the company, withdrew from its capital.

Primary placement

On May 4, 2007, during a public offering (Initial Public Offering, IPO), the company placed its shares in the Russian Trading System(RTS) and Global Depository Receipts (GDR) on the London Stock Exchange (London Stock Exchange, LSE). Investors showed interest in the company's shares, and the placement passed at the upper limit of the established range - $58.2 per share and $14.55 per depositary receipt. The capitalization of the company following the results of the IPO amounted to $2.2 billion.

Pharmstandard placed 40% of its authorized capital on the Russian and London stock exchanges, raising $880 million before the option is exercised. Citi and UBS Investment Bank became global co-coordinators of the placement.

Pharmstandard is the first Russian pharmaceutical company whose shares are listed on the international market.

Activity

By the beginning of 2013, Pharmstandard owned seven pharmaceutical plants and one plant for the production of medical equipment and instruments. The company's factories produce more than 250 types of drugs (more than 120 items are included in the List of Essential Drugs (VED)). The company's capacity is more than 1.7 billion packages per year.

Pentalgin tablet

• "Pharmstandard-Ufavita" in Ufa. The factory was founded in 1916. General Director - Vladimir Kreyman. The number of employees is 1400 people. Main brands: Complivit, Biosulin, Rastan, Neypomax, Phosphogliv.
• "Pharmstandard-Fitofarm-NN" in Nizhny Novgorod
• "Pharmstandard-Tomskhimfarm" in Tomsk. The factory was founded in 1913. General Director - Andrey Skorokhod. The number of employees is over 600 people. Main brands: Arbidol, Amiksin, Imudon, Thermikon, IRS-19.
• "Pharmstandard-Leksredstva" in Kursk. The factory was founded in 1922. General Director - Eugene Prokhoda. The number of employees is over 1450 people. Main brands: Arbidol, Pentalgin, Phosphogliv.
• Tyumen plant of medical equipment and instruments. The plant was founded in 1962. General Director - Alexander Nizovtsev. The main specialization of the plant is single-use medical products (needles, syringes, droppers, catheters, urinals), sterilization equipment (steam sterilizers), water distillers, water collectors.

The Pharmstandard group of companies produces more than 250 types of drugs, including drugs for the treatment of cardiovascular diseases, diabetes, growth hormone deficiency, gastroenterological, neurological, infectious diseases, metabolic disorders, oncological and other diseases.

Performance indicators

• 2013 - 55.92 billion rubles. (growth compared to 2012 by 8.8%);
• 2012 - 51.391 billion rubles (growth compared to 2011 by 20.5%);
• 2011 - 42.653 billion rubles. (growth compared to 2010 by 43.7%);
• 2010 - 29.694 billion rubles. (growth compared to 2009 by 23.2%);
• 2009 - 24.096 billion rubles. (growth compared to 2008 by 68.1%).

Net profit in different years was:

• 2012 - 9.96 billion rubles. (growth by 12.8%);
• 2011 - 8.832 billion rubles. (growth by 23.3%);
• 2010 - 7.163 billion rubles. (growth by 4.5%);
• 2009 - 6.852 billion rubles. (growth by 96%).

Export

Pharmstandard exports products to 16 countries:

IN strategic plans includes business expansion and development in:

• Venezuela, Argentina, Nicaragua, Nigeria, Egypt, Iran, Iraq, Afghanistan, UAE.

According to the results of 2012, the export sales of the company's pharmaceutical products increased by 41.1% and amounted to 1,320.9 million rubles compared to 935.9 million rubles in 2011.

Awards and ratings

The drug Arbidol, which is included in the company's portfolio, took the 1st line in terms of sales in 2007 on Russian market over-the-counter drugs

Pharmstandard is the leader of the domestic pharmaceutical industry. According to Pharmexpert CMI data, based on the results of 2008, Pharmstandard took the first position in the retail segment of the market and the second position among all pharmaceutical companies, being the only domestic company in the top ten in the pharmaceutical market in Russia.

Pharmstandard produces more than 200 types of drugs for the treatment of cardiovascular diseases, diabetes mellitus, growth hormone deficiency, gastroenterological, neurological, infectious diseases, metabolic disorders, oncological and other diseases. Of these, 90 drugs are included in the "List of vital drugs" (VED).

Pharmstandard has agreements with the company "Grindeks", Latvia on the exclusive distribution and promotion of the drug "Mildronate", as well as with the company "Solvay Pharmaceuticals", France for the production of drugs "IRS 19" and "Imudon".

In the period from 2004-2009. more than 39 new medicines have been developed and introduced. Priority directions development are genetically engineered, vitamin and mineral, cardiological and gastroenterological preparations. The company actively cooperates with leading scientific institutions of the country in the development of new high-tech medicines.

The company includes 4 pharmaceutical Russian factory, with a total production capacity of 1.3 billion packs per year. Six production lines of Pharmstandard-Leksredstva PJSC received certificates of compliance with EU GMP international standards. PJSC "Pharmstandard - Leksredstva" - the first Russian enterprise included in the European database EudraGMP (European Medicines Agency, EMEA). All production facilities of the company fully comply with the requirements of Russian standards.

In addition to the pharmaceutical business, Pharmstandard manufactures and sells high-tech medical equipment and disposable medical products.

Pharmstandard has invested more than 3 billion rubles in the modernization and development of its enterprises since the beginning of 2004.

Since 2005, Pharmstandard has included PJSC Tyumen Plant of Medical Equipment and Instruments (TZMOI), the leader of the domestic market of medical equipment and disposable products.

TZMOI was founded in April 1962 and has been developing, designing and manufacturing medical steam sterilizers for almost 50 years. The product line includes models with a sterilization chamber volume from 10 to 2250 dm3. Along with simple models of sterilizers with semi-automatic control, equipment is produced with automatic microprocessor control, forevacuum, devices for documenting and recording sterilization parameters, the ability to computer diagnostics, as well as universal type sterilizers (for processing medical devices, textile materials and medicinal solutions). In addition to sterilizers, the medical equipment group includes water distillers, water storage tanks, disinfection boilers, as well as spare parts.

Since 1989, TZMOI was one of the first enterprises in Russia to launch mass production of single-use injection syringes. In this commodity group includes special syringes for insulin and tuberculin with a capacity of 1 ml, as well as two-piece syringes with a capacity of 2 (2.5) to 20 ml. In addition to syringes, the group of single-use products includes injection needles, catheters, probes, urinals, tips for Esmarch's mug.

The quality management system of TZMOI is certified for compliance international standards quality standards ISO 9001:2000, ISO 13485:2003. Syringes and needles have an EC-certificate that allows you to mark these products with the "CE" mark.

Assignees:

Predecessors:

Activities:

main (according to OKVED code rev.2): 46.46.1 - Wholesale of pharmaceutical products

Additional activities according to OKVED 2:

Founders:

Is or was a former founder of the following organizations:

Registration in the Pension Fund Russian Federation:

Registration number: 060006007494

Date of registration: 15.08.2007

Name body of the FIU: State institution - Main Directorate of the Pension Fund of the Russian Federation No. 5 Directorate No. 6 of Dolgoprudny, Moscow Region

State registration registration number of entries in the Unified State Register of Legal Entities: 2075047151848

27.08.2007

Registration with the Social Insurance Fund of the Russian Federation:

Registration number: 027400801050261

Date of registration: 27.09.2007

Name of the FSS authority: Branch №26 State institution- Moscow Regional Branch of the Social Insurance Fund of the Russian Federation

State registration registration number of entries in the Unified State Register of Legal Entities: 2075047173485

Date of entry in the Unified State Register of Legal Entities: 12.10.2007

According to rkn.gov.ru dated January 31, 2020, according to the TIN, the company is included in the register of operators processing personal data:

Registration number:

Date of registration of the operator in the register: 06.11.2018

Grounds for entering the operator in the register (order number): 245

Operator location address: 141700, Moscow region, Dolgoprudny, Likhachevsky passage, 5B

Start date of personal data processing: 05.05.2006

Subjects of the Russian Federation on the territory of which the processing of personal data takes place: Moscow, Moscow region

Purpose of personal data processing: compliance with and fulfillment of the requirements of labor, tax and labor protection legislation of the Russian Federation, ensuring the maintenance personnel work, accounting and tax accounting, remuneration and bonuses to employees, training and advanced training of employees, provision of compensations and benefits to employees and relatives of employees, including voluntary insurance, accident insurance, provision of vouchers to children's camps, gifts to employees' children, provision of employees with company cars as part of the execution their labor functions, organization of trips and business trips, organization of employee training, formation personnel reserve and selection of candidates for vacant positions, ensuring internal order, security and safety of property, ensuring access control, identifying conflicts of interest, carrying out marketing activities and promoting products on the market, including the implementation of information mailings and business contacts with healthcare professionals, compliance with and compliance with the requirements of the legislation of the Russian Federation and other regulatory legal acts in the field of health care and the circulation of medicines, providing reliable information about products and new drugs, monitoring product safety, ensuring interaction with counterparties and fulfilling obligations under concluded agreements, carrying out due diligence measures when choosing counterparties, creating publicly available sources of personal data , including directories, address books, internal corporate resources, compliance with and compliance with the requirements of the legislation of the Russian Federation and other regulatory legal acts in the field of personal data protection.

Description of the measures provided for by Art. 18.1 and 19 of the Law: Local acts on the processing and protection of personal data, as well as local acts establishing procedures aimed at preventing and detecting violations of legislation in the field of personal data protection, have been developed and approved. A person responsible for the processing of personal data has been appointed. Implemented internal control compliance of the processing of personal data with this Federal Law and the regulations adopted in accordance with it legal acts, requirements for the protection of personal data, an annual audit of the fulfillment of the requirements is provided current legislation. Employees directly involved in the processing of personal data are familiar with the provisions of the legislation of the Russian Federation on personal data, including the requirements for the protection of personal data, documents defining the organization's policy regarding the processing of personal data, local acts on the processing and protection of personal data. Published and posted on the website of the organization a document defining the policy regarding the processing of personal data, to information about the implemented requirements for the protection of personal data. Accounting for machine carriers of personal data is provided in accordance with the requirements of the current legislation as part of the inventory technical means. The means of protection that have passed in in due course compliance procedure. The facts of unauthorized access to personal data are detected and appropriate measures are taken. Recovery of personal data modified or destroyed due to unauthorized access to them is provided. A system of access to personal data processed in the personal data information system has been developed, as well as registration and accounting of all actions performed with personal data in the personal data information system. Personal data is available to a strictly defined circle of employees, security and fire alarms are installed in the building, physical protection of the information system (hardware and information carriers), which provides for control of access to the premises of the information system by unauthorized persons, the presence of reliable barriers to unauthorized entry into the premises of the information system and media storage. Access to server rooms is limited by access control means (access control). Access of unauthorized persons to the premises of the company is possible only if accompanied by the inviting employees. The safety of the server equipment used in the processing of personal data is ensured by restricting access to the premises where the server equipment is located. The safety of personal data carriers is ensured by means of access control measures and access control to the respective media.

Categories of personal data: biometric personal data, last name, first name, patronymic, year of birth, month of birth, date of birth, place of birth, address, marital status, social status, property status, education, profession, income, health status, citizenship, address of registration and actual residence, data of an identity document (series, number, date of issue, name of the authority that issued the document), information of a foreign passport, information on military registration ( military rank, date of issue of the military ID, category of validity, reserve category and profile, name of the commissariat that issued the military ID, attitude to military duty, series and number of the military ID), information about education, qualifications and availability of special, knowledge or special, training (series , number, date of issue of a diploma, certificate, certificate or other graduation document educational institution, name of the educational institution, date of commencement and completion of studies, faculty or department, qualification and specialty upon graduation from the educational institution, academic degree, academic title, possession foreign languages), age, information sick leave, the amount of temporary disability benefits, bank account information necessary for calculating and paying salaries, information about the amount of salary, information about bonuses paid, data on allowances, taxes, deductions, information about residency / non-residence, position, information about labor activity, information about employers, promotions, disciplinary actions, transitions to new position/ place of work, reasons for dismissal, data on the investigation and registration of accidents at work and occupational diseases, in accordance with the legislation of the Russian Federation, which are not medical secrets and related to the issue of the possibility of performing labor function, information about social benefits and about social status(series, number, date of issue, name of the authority that issued the document that is the basis for granting benefits and status, and other information), information about awards (encouragements), honorary titles, details of the document confirming the right to receive benefits / material assistance, SNILS , TIN, information about pension contributions, driver's license data, category, driving experience, car make, car model, car VIN, state. number, accident data, contact phone number, address Email, visa, work permit and legal status, country of residence, medical policy data (CMI / VMI / NS), data of a document confirming the occurrence of an insured event, data on an undesirable event, information on the time of entry and exit of visitors from the territory of the company.

Categories of subjects whose personal data are processed: Owned by employees of Pharmstandard JSC, laid-off employees, relatives of employees, candidates for vacant positions, employees of counterparties in the framework of the fulfillment of obligations under concluded contracts, contractors under civil law contracts, specialists involved in the healthcare system of the Russian Federation, including those belonging to medical workers(including doctors of various specialties), representatives and administrators of medical institutions, pharmacies, consumers of pharmaceutical products, visitors to the company's office, employees of the company's affiliates.

List of actions with personal data: By: collecting, recording, systematizing, accumulating, storing, clarifying (updating, changing), extracting, using, transferring (distributing, providing, accessing), deleting, destroying personal data, blocking personal data

Processing of personal data: mixed, with transmission over the internal network legal entity, with transmission over the Internet

Legal basis for the processing of personal data: Guided by the Constitution of the Russian Federation, Civil Code RF, Labor Code Russian Federation, Tax Code of the Russian Federation, Civil Procedure Code of the Russian Federation, Arbitration Procedure Code of the Russian Federation, Criminal Code of the Russian Federation, Criminal Procedure Code of the Russian Federation, Code of Administrative Offenses of the Russian Federation, federal law dated April 6, 2011 No. 63-FZ “On electronic signature”, Federal Law of December 26, 1995 No. 208-FZ “On joint-stock companies”, Federal Law No. 39-FZ of April 22, 1996 “On the Market valuable papers”, Regulations on the disclosure of information by issuers of emissive securities, approved by order of the Federal Financial Markets Service of Russia dated 04.10.2011 N 11-46 / pz-n, Requirements for the protection of personal data during their processing in information systems personal data, approved by Decree of the Government of the Russian Federation of November 1, 2012 No. 1119, Regulations on the peculiarities of processing personal data carried out without the use of automation tools, approved by Decree of the Government of the Russian Federation of September 15, 2008 No. 687, Law of the Russian Federation of April 19, 1991 No. 1032-1 "On Employment of the Population in the Russian Federation”, Federal Law No. 27-FZ of April 1, 1996 “On Individual (Personalized) Accounting in the Compulsory Pension Insurance System”, Federal Law No. 125-FZ of July 24, 1998 “On Compulsory Social Insurance against Accidents at production and occupational diseases”, Federal Law of 24.07.2009 No. No. 212-FZ "On insurance contributions to the Pension Fund of the Russian Federation, the Social Insurance Fund of the Russian Federation, the Federal Compulsory Medical Insurance Fund", Federal Law of December 6, 2011 No. 402-FZ "On Accounting", Federal Law of November 21, 2011 No. 323-FZ "On the Fundamentals of Protecting the Health of Citizens", Federal Law No. 61-FZ of April 12, 2010 "On the Circulation of Medicines", Federal Law No. 127-FZ of August 23, 1996 "On Science and State Scientific and Technical Policy", Order Ministry of Health of Russia dated 01.04.2016 No. 200N "On approval of the rules of good clinical practice", Letter of Roszdravnadzor dated 15.07.2009 N 01I-396 / 09 "On the Guidelines for good practice in the manufacture of medicines", Federal Law dated 07.02.1992 No. 2300-1 “On Protection of Consumer Rights”, Federal Law No. 125-FZ of October 22, 2004 “On Archiving in the Russian Federation”, requirements of GOST R 52379-2005 “Good Clinical Practice”, Order of the Ministry of Health of the Russian Federation of April 1, 2016 No. 200n "On approval of the rules of good clinical practice", Letter of Roszdravnadzor dated July 15, 2009 No. 01I-396 / 09 "On the Guidelines for good practice in the production of medicines", the requirements of GOST R 52249-2009 "National standard for the production and quality control of medicines (GMP)" (approved by Order of Rostekhregulirovanie of 20.05.2009 N 159-st), contracts, agreements on the terms of commissioning the processing of personal data, as well as the Charter of Pharmstandard JSC.

Availability of cross-border transmission: Yes

Database location details: Russia

Information on income and expenses according to the Federal Tax Service dated October 19, 2019 according to TIN 0274110679:

Information on the amounts of taxes and fees paid according to the Federal Tax Service dated October 19, 2019 according to TIN 0274110679:

The holding is huge and heterogeneous, as luck would have it. For some, luck is to kick the bullshit, for someone - to develop and work in a good team. There are departments for both the first and the second. In the "fields" is also different. Do not judge by hrs, they are strange here)

Eat great amount characters with conceit on a universal scale and negative efficiency. And the budget for their maintenance is a kind of charity in favor of mentally disabled people.

07.11.19 18:14 MoscowWorker,

Office next to the subway.

The vacancy of an analyst is updated from time to time, it hangs constantly. At the interview, it is positioned that analysts have been working here for a long time. This is very pathetically stated by the head of the department. A stupid mindfulness test for third graders. Lack of feedback.

01.10.19 13:48 in the Moscow regionCoca Cola,

a good VMI, if you do not take into account dentistry, for which you can only do an ultrasound cleaning of your teeth once a year, a white salary on a VTB card or Sberbank, that's all

gossip and blather. if you came according to the announcement, about any career growth you can't even dream. I will separately tell you about the position of "Project Administrator" with Comrade Zyryanov I.B. If you value yourself even a little bit, run away from here, I'm serious. At the interview, everyone colorfully tells: what a wonderful team in IT (lies, everyone follows each other and knocks on Zyryanov to ...

21.03.19 11:48 MoscowLelya Krok,

Nice office

This was the first place I was asked when I was going to have my third child. And I had a lot of interviews. It was tempting to ask if they were asking these kinds of questions to men. In addition, they have 3 or 4 rounds of interviews. At the same time, the vacancy has been hanging for exactly more than six months. They talked down (basically, the head of the department, HR is still nothing). They tortured me for a long time about my life path ...

26.10.18 22:15MoscowBuyer,

26.10.18 22:13MoscowBuyer,

Feedback from the buyer. Medicines are mostly fake. Mukaltin, well, what the hell, it won't do anyone any good or harm either. Pure soda tablets. That Mukaltin, which we are treated for cough and does not smell. They sell just pressed soda. Tip: do not buy drugs from this company! It's empty!

13.09.18 15:43 in the Moscow regionformer employee,

A stable company, salary is not delayed, there are bonuses, medical insurance is normal, especially for managerial positions, corporate parties, a canteen, sometimes they can even be sent to study for courses (rarely). A great opportunity for growth - unless of course you came not from the street, but a relative or friend of someone from the leadership. The director at Pharmstandard LLC Darko Y. is smart, knowledgeable and decent, it’s a pity that there are two deputies for them, ...

If you are an ordinary employee, there is little good, especially in the procurement department of LLC, there are two deputies Mashnikova and Strigulin. authoritarian style communication. If you are a decent person and a professional, it will be difficult for you here, because. you have to show a lot of devotion...

05.02.18 16:21 MoscowMasha Anastasia,

I worked for over half a year. Leadership: Podgorbunskikh N.I., Usmanova E. and Mr. Tolstova - completely inadequate. They do not know what they want from employees, they are rude, bring to tears. They took on one position, the duties were completely different. Sneaky surveillance of people, a report on the work every day about your every step (when you went to the toilet, ate, sat on the Internet) Low and disgusting, and this, for a minute ...